IQVIA sees U.S. MASH diagnostics using Genfit technology topping USD 1.5 billion sales by 2033

• Genfit flagged U.S. peak sales above USD 1.5 billion by 2033 for MASH diagnostics using its NIS technology, citing IQVIA.
• Annual U.S. testing volume projected above 7 million tests by 2033, targeting 86 million monitored patients with MASLD-related risk factors.
• Adoption outlook tied to expanding reimbursement, guideline inclusion, rising disease awareness, and wider use beyond specialists into primary care.
• Medicare reimbursement for Labcorp’s NASHnext test became effective in August 2026 under the Clinical Laboratory Fee Schedule, supporting uptake.
• Diagnostics demand expected to accelerate from 2028 as additional MASH therapies expand screening and monitoring needs.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genfit SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609090130OMX_____CNEWS_EN_GNW1001261717_en) on September 09, 2026, and is solely responsible for the information contained therein.